Prilosec OTC Patent Extension Request “Compels” Name Change – Mylan
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca's efforts to extend a patent for Prilosec OTC bolster the case for mandating a name change for the nonprescription product, Mylan says in Oct. 29 comments to FDA